Skip to content

MIP Discovery

Invested in:
Calculus VCT

MIP Discovery is a novel affinity reagent company. Founded in 2015 as a spin out from the University of Leicester to commercialise various forms of Molecularly Imprinted Polymers (MIPs), sometimes called ‘plastic antibodies’.

The Company’s proprietary technology includes a novel method to make nanoMIPs which circumvents the drawbacks of traditional MIP manufacturing methods. The robust nature of MIPs and nanoMIPs make them ideal reagents for a wide range of applications including point-of-care diagnostics and in field-based testing. They can withstand harsh chemical environments, such as extremes of pH, seawater or high concentrations of organic solvents. MIPs have successfully been created and deployed against all major target classes including peptides, proteins and other macromolecular structures, as well as smaller chemical entities such as drugs, their metabolites and commonly used biochemical species such as enzyme cofactors. Using the proprietary nanoMIP design and development process, MIP Discovery can provide a proven nanoMIP within just two weeks of receiving the target.


The team has significant industry experience being chaired by Jim Reid who held senior positions at Axis-Shield and Roche. The investment from Calculus Capital will enable MIP Discovery to further develop in house assets for future licensing, increase revenues, bring products to market and continue development of the platform.

Latest News

Calculus backs MIP Diagnostics with further funding

MIP Diagnostics, a UK nanotechnology business has secured increased investment of its previous round of funding, totalling £7.3M. The joint investment comes from Mercia Asset Management, Calculus Capital, Downing Ventures and BGF, along with an original angel investor.

Read more

MIP Diagnostics: Synthetic antibodies to increase accuracy of COVID-19 antigen tests

MIP Diagnostics, which produces synthetic antibodies, has launched a new product that could improve the success of rapid sensors in detecting COVID-19. MIP Diagnostics has today announced the launch of its COVID-19 nanoMIP for diagnostic sensors, a synthetic alternative to antibodies that offers ultra-high sensitivity for the next wave of COVID-19 antigen detecting devices. nanoMIPs … Continued

MIP Diagnostics Signs Significant Commercial Agreement for Novel Security Applications

MIP Diagnostics Ltd, the Molecularly Imprinted Polymers (MIPs) specialist based in Sharnbrook, United Kingdom, has announced a collaborative agreement with commercial partners for the co-development and license of a novel MIP-based system with specific applications in the security field. The long-term benefits of the deal could have ground breaking implications in the target applications and generate … Continued